Evidence map›Paper›PMID 27860402›Full record

ArticleChemMedChem2017

Characterization of a Cell-Penetrating Peptide with Potential Anticancer Activity.

Anja Gronewold, Mareike Horn, Ivan Ranđelović, József Tóvári, Sergio Muñoz Vázquez, Klaus Schomäcker, Ines Neundorf

Erratum issuedAbstract read
In one paragraph

Article in ChemMedChem, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Building up PtChembiochem : a European journal of chemical biology · 2021
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Internalization mechanisms of cell-penetrating peptides.Beilstein journal of nanotechnology · 2020
    Review
  17. Review
  18. Article
  19. Unique auto-ubiquitination activities of artificial RING fingers in cancer cells.Protein science : a publication of the Protein Society · 2018
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Anja GronewoldUniversity of Cologne, Department of Chemistry, Institute of Biochemistry, Zuelpicher Str. 47, 50674, Cologne, Germany.
Mareike HornUniversity of Cologne, Department of Chemistry, Institute of Biochemistry, Zuelpicher Str. 47, 50674, Cologne, Germany.
Ivan RanđelovićNational Institute of Oncology, Department of Experimental Pharmacology, Ráth Gy. u. 7-9, 112, Budapest, Hungary.
József TóváriNational Institute of Oncology, Department of Experimental Pharmacology, Ráth Gy. u. 7-9, 112, Budapest, Hungary.
Sergio Muñoz VázquezUniversity Hospital of Cologne, Department of Nuclear Medicine, Kerpener Str. 62, 50937, Cologne, Germany.
Klaus SchomäckerUniversity Hospital of Cologne, Department of Nuclear Medicine, Kerpener Str. 62, 50937, Cologne, Germany.
Ines NeundorfUniversity of Cologne, Department of Chemistry, Institute of Biochemistry, Zuelpicher Str. 47, 50674, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell-penetrating peptides (CPPs) are still an interesting and viable alternative for drug delivery applications. CPPs contain considerably high amounts of positively charged amino acids, imparting them with cationic character. Tumor cells are characterized by an enhanced anionic nature of their membrane surface, a property that could be used by CPPs to target these cells. We recently identified a branched CPP that displays a high internalization capacity while exhibiting selectivity for certain tumor cell types. In this study we elucidated this observation in greater detail by investigating the underlying mechanism behind the cellular uptake of this peptide. An additional cytotoxicity screen against several cancer cell lines indeed demonstrates high cytotoxic activity against cancer cells over normal fibroblasts. Furthermore, we show that this feature can be used for delivering the anticancer drug actinomycin D with high efficiency in the MCF-7 cancer cell line.

Indexed as

Antineoplastic AgentsCell Line, TumorCell-Penetrating PeptidesCell ProliferationCell SurvivalDactinomycinDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansStructure-Activity RelationshipAntineoplastic AgentsCell-Penetrating PeptidesDactinomycinanticancer activitycell-penetrating peptideslytic peptidestumor cellstumor targeting

Identifiers

PMID27860402
PMCPMC5516705

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.